Eosinophilic Esophagitis
Also known as: EoE
Methodology & AI Transparency ⓘ
Eosinophilic Esophagitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is eosinophilic esophagitis (EoE)? Eosinophilic esophagitis (EoE) is a chronic disease of the esophagus.
- 2 Real-world patient consensus: Diagnostic registry R11.9: Eosinophilic Esophagitis is managed within GERD & Stomach (aka EoE).
- 3 Typical cash cost range: Primary evaluation for Eosinophilic Esophagitis incorporates H. pylori non-invasive in Eosinophilic Esophagitis (R11.9: testing) and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Eosinophilic Esophagitis: Hemoglobin & Serum in Eosinophilic Esophagitis (R11.9: Ferritin) (Ferritin > 50 ng/mL (no occult loss) (R11.9)) and Serum Vitamin B12 in Eosinophilic Esophagitis (R11.9: & Magnesium (chronic).
Ask our AI Specialists anything about Eosinophilic Esophagitis
What Is Eosinophilic Esophagitis?
What is eosinophilic esophagitis (EoE)? Eosinophilic esophagitis (EoE) is a chronic disease of the esophagus. Your esophagus is the muscular tube that carries food and liquids from your mouth to the stomach. If you have EoE, white blood cells called eosinophils build up in your esophagus. This causes damage and inflammation, which can cause pain, trouble swallowing , and food getting stuck in your throat. EoE is rare. But because it is a newly recognized disease, it is being diagnosed more often. Some people who think that they have reflux (GERD) may actually have EoE. What causes eosinophilic esophagitis (EoE)? Researchers are not certain about the exact cause of EoE.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in gerd & stomach, Eosinophilic Esophagitis (R11.9) involves gastroduodenal mucosal bicarbonate in Eosinophilic Esophagitis (R11.9: barrier disruption). Cross-referenced with NIH MeSH (Eosinophilic Esophagitis), progression correlates with shifts in Hemoglobin & Serum in Eosinophilic Esophagitis (R11.9: Ferritin) (Ferritin > 50 ng/mL (no occult loss) (R11.9)).
Common Symptoms & Clinical Signs
- • Have other allergic diseases, such as hay fever , eczema , asthma and food allergies
- • Have family members with EoE
- • Presentation of Eosinophilic Esophagitis (R11.9): epigastric burning, early in Eosinophilic Esophagitis (R11.9: satiety, or upper-abdominal)
- • Secondary Eosinophilic Esophagitis clinical sign: chronic throat clearing, in Eosinophilic Esophagitis (R11.9: hoarseness, nocturnal cough,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Eosinophilic Esophagitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R11.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Acid Reflux, GERD & Upper GI Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Hemoglobin & Serum in Eosinophilic Esophagitis (R11.9: Ferritin) | Ferritin > 50 ng/mL (no occult loss) (R11.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Eosinophilic Esophagitis (R11.9: & Magnesium (chronic) | B12 > 450 pg/mL; Mg >= 2.0 mg/dL (R11.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: H. pylori Stool in Eosinophilic Esophagitis (R11.9: Antigen or Urea) | Negative (R11.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Eosinophilic Esophagitis
Treatment selection for Eosinophilic Esophagitis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Eosinophilic Esophagitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic: What a 213-Participant Study Found In patients with EoE, BOS 2.0 mg twice daily was superior to placebo in improving histologic, symptomatic, and endoscopic outcomes over 12 weeks. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2022-03-15 • Phase III Randomized Trial | N = 213 | 88/100 | PMID 33887475 ↗ |
| Can This Approach Help? Inside the Latest Research on Dupilumab improves clinical outcome assessments in children with eosinophilic Improvements with dupilumab vs. BMC gastroenterology • 2026-07-29 • Phase III Randomized Trial | N = 37 | 88/100 | PMID 42928144 ↗ |
| Can This Approach Help? Inside the Latest Research on Patient experience with eosinophilic esophagitis symptoms and impacts on daily This study highlighted emotional and social burdens of EoE. Journal of patient-reported outcomes • 2025-01-08 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39777591 ↗ |
| Can This Approach Help? Inside the Latest Research on Safety and real-world benefits of Mepolizumab in Hypereosinophilic Syndrome: An Extended mepolizumab treatment was associated with a positive benefit-risk profile. The journal of allergy and clinical immunology. In practice • 2021-12-15 • Phase III Randomized Trial | N = 52 | 88/100 | PMID 34389506 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Extended Induction With Tofacitinib for the Treatment of The majority of patients achieved a clinical response after 8 or 16 weeks' induction therapy with tofacitinib 10 mg BID. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2022-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33127596 ↗ |
Eosinophilic Esophagitis Patient Community & “People Like Me” Threads
Filter Eosinophilic Esophagitis community threads and patient logs by age, biological sex, dosage, and treatment duration.